Clark Capital Management Group, Inc.
Position in RPRX — Royalty Pharma plc
CIK 1352187
PHILADELPHIA, PA
Position in RPRX
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$93,244,578
+$14,575,314 QoQ
Shares Held
1,663,003
+1.4% QoQ
Ownership
0.289%
of shares outstanding
% of Portfolio
0.68%
of 13F equity value
Holder Rank
#41
of 646 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Clark Capital Management Group, Inc. holds $136,817,304 across 5 Biotechnology names. RPRX ranks #1 (68.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
This page
|
1,663,003 | $93,244,578 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
231,956 | $18,155,196 | |
| 3 | EXEL |
Exelixis, Inc.
|
271,878 | $14,792,881 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
32,948 | $10,414,533 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
423 | $210,116 |
All Filings in RPRX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $93,244,578 | 1,663,003 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $78,669,264 | 1,639,968 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $67,767,218 | 1,753,810 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $61,804,985 | 1,751,842 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||